Dyslipidemia resident survival guide: Difference between revisions
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
Line 30: | Line 30: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |A01='''Identify risk factors for CAD'''<br><br> | ||
'''''Major risk factors:'''''<br> | |||
❑ Advanced age <br> | |||
❑ ↑ total serum cholesterol <br> | |||
❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C)<br> | |||
❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5))<br> | |||
❑ ↓ HDL-C<br> | |||
❑ Diabetes mellitus<br> | |||
❑ Hypertension<br> | |||
❑ Cigarette smoking<br> | |||
❑ Family history of CAD<br><br> | |||
Additional risk factors:<br> | |||
❑ Obesity, especially abdominal<br> | |||
❑ Family history of hyperlipidemia<br> | |||
❑ Small, dense LDL-C<br> | |||
❑ ↑ Apo-B<br> | |||
❑ ↑ LDL particle number (measured by ApoB)<br> | |||
❑ Fasting/postprandial hypertriglyceridemia<br> | |||
❑ Polycystic ovarian syndrome<br> | |||
❑ Dyslipidemic triad<br><br> | |||
Non-traditional risk factors:<br> | |||
❑ ↑ lipoprotein<br> | |||
❑ ↑ clotting factors<br> | |||
❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2)<br> | |||
❑ Hyperhomocysteinemia<br> | |||
❑ ApoE4 isoform<br> | |||
❑ ↑ uric acid}} | |||
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |B01=Determine the 10-year risk of coronary event using ANY of the following assessment tools:<br> | ||
❑ Framingham Risk Assessment Tool | |||
❑ Reynolds Risk Score (To be redirected to Reynolds Risk Score website, click [http://www.reynoldsriskscore.org/ here])}} | |||
{{familytree | | | | | |,|-|-|-|v|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | |,|-|-|-|v|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | C01 | | C02 | | | | C03 | | C04 | {{familytree | | | | | C01 | | C02 | | | | C03 | | C04 | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | |`|-|-|-|^|-|-|v|-|-|^|-|-|-|'| | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | |`|-|-|-|^|-|-|v|-|-|^|-|-|-|'| | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}} | ||
Line 51: | Line 106: | ||
{{familytree | | | |!| | | |!| | | |,|-|-|^|-|-|.| | | | | | | |,|-|^|-|.| | | | | | | | | | | | |}} | {{familytree | | | |!| | | |!| | | |,|-|-|^|-|-|.| | | | | | | |,|-|^|-|.| | | | | | | | | | | | |}} | ||
{{familytree | | | H01 | | H02 | | H03 | | | | H04 | | | | | | H05 | | H06 | | | | | | | | | | | |}} | {{familytree | | | H01 | | H02 | | H03 | | | | H04 | | | | | | H05 | | H06 | | | | | | | | | | | |}} | ||
Revision as of 15:22, 20 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Classification
Causes
Secondary causes of dyslipidemia may cause either an increase in total-cholesterol & low density lipoprotein-cholesterol (LDL-C) or an increase in total triglycerides & very low density lipoprotein cholesterol (VLDL-C). Common causes are listed below.
Increase in Total Cholesterol and LDL-C
- Hypothyroidism
- Nephrosis
- Dysgammaglobulinemia (systemic lupus erythematosus, multiple myeloma)
- Cholestatic hepatic diseases due to abnormal lipoproteins (e.g. primary biliary cirrhosis)
- Administration of protease inhibitors (treatment for HIV infection)
- Administration of progestin or anabolic steroids
Increase in Total Triglycerides and VLDL-C
- Chronic kidney disease
- Type 2 diabetes mellitus
- Obesity
- Excessive alcohol intake
- Hypothyroidism
- Administration of anti-hypertensive therapy (thiazide diuretics or B-blockers)
- Administration of corticosteroids
- Severe stress that increases endogenous corticosteroid concentration
- Elevated concentrations of estrogen (administration of oral (not transdermal) estrogen therapy, oral contraceptives, or pregnancy)
- Administration of protease inhibitors (treatment for HIV infection)
To view a comprehensive list of dyslipidemia causes, click here
Screening
Abbreviations: ASA: American society of anesthesiologists; BP: Blood Pressure; CCS: Canadian cardiovascular society; CrCl: Creatinine clearance; CXR: Chest X-ray; DNI: Do not intubate; DNR: Do not resuscitate; ECG: Electrocardiogram; eGFR: estimated glomerular filtration rate; HR:Heart rate; INR: International normalized ratio; LMWH: Low molecular weight heparin; LV: Left ventricle; LVED: Left ventricular ejection fraction; NOAC: Novel oral anticoagulant; NPO: Nothing per os; PMI: Point of maximal impulse; PT: Prothrombin time; RR: Respiratory rate; SpO2: Oxygen saturation; T: Temperature; VT: Ventricular tachycardia
Identify risk factors for CAD Major risk factors: ❑ Advanced age ❑ ↑ total serum cholesterol ❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C) ❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5)) ❑ ↓ HDL-C ❑ Diabetes mellitus ❑ Hypertension ❑ Cigarette smoking ❑ Family history of CAD ❑ Obesity, especially abdominal ❑ Family history of hyperlipidemia ❑ Small, dense LDL-C ❑ ↑ Apo-B ❑ ↑ LDL particle number (measured by ApoB) ❑ Fasting/postprandial hypertriglyceridemia ❑ Polycystic ovarian syndrome ❑ Dyslipidemic triad ❑ ↑ lipoprotein ❑ ↑ clotting factors ❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2) ❑ Hyperhomocysteinemia ❑ ApoE4 isoform | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Determine the 10-year risk of coronary event using ANY of the following assessment tools: ❑ Framingham Risk Assessment Tool ❑ Reynolds Risk Score (To be redirected to Reynolds Risk Score website, click here) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ C01 }}} | {{{ C02 }}} | {{{ C03 }}} | {{{ C04 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ D01 }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ E01 }}} | {{{ E02 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ F01 }}} | {{{ F02 }}} | {{{ F03 }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ G01 }}} | {{{ G02 }}} | {{{ G03 }}} | {{{ G04 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ H01 }}} | {{{ H02 }}} | {{{ H03 }}} | {{{ H04 }}} | {{{ H05 }}} | {{{ H06 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ I01 }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ J01 }}} | {{{ J02 }}} | {{{ J03 }}} | {{{ J04 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ K01 }}} | {{{ K02 }}} | {{{ K03 }}} | {{{ K04 }}} | {{{ K05 }}} | {{{ K06 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{{ L01 }}} | {{{ L02 }}} | {{{ L03 }}} | {{{ L04 }}} | {{{ L05 }}} | {{{ L06 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||